Patents by Inventor Pascal Francois
Pascal Francois has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11998120Abstract: A sunshade for an outdoor public space, having a pane made from an at least partially opaque material and a mount adapted to be fixed to the ground and rotatively supporting the pane for rotation about a vertical axis of rotation. The sunshade has a rotation control apparatus adapted to control rotation of the pane.Type: GrantFiled: May 21, 2021Date of Patent: June 4, 2024Assignee: JCDecaux SAInventors: Jean Francois Nion, Pascal Postolle, Cedric Davet
-
Patent number: 11974997Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.Type: GrantFiled: October 5, 2021Date of Patent: May 7, 2024Assignee: GenfitInventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
-
Publication number: 20240115655Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: ApplicationFiled: February 28, 2023Publication date: April 11, 2024Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Publication number: 20240091029Abstract: A system for guiding a glenoid prosthesis is disclosed. The system includes a glenoid guide that includes: a guide feature; at least three arms having a first end coupled with the guide feature and a second end disposed away from the guide feature; at least three peripheral pegs, each peripheral peg extending from the second end of a corresponding arm and includes an engagement surface configured to engage the scapula of the patient; and a strut extending laterally from the guide feature.Type: ApplicationFiled: November 8, 2023Publication date: March 21, 2024Applicant: Tornier SASInventors: Pierric Deransart, Emmanuel Francois Marie Lizee, Delphine Claire Michelle Henry, Jean Chaoui, Gilles Walch, Pascal Boileau
-
Publication number: 20240076317Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.Type: ApplicationFiled: April 11, 2023Publication date: March 7, 2024Inventors: Cedric Francois, Pascal Deschatelets
-
Publication number: 20170315906Abstract: The present invention concerns a method for allocating a space of predetermined size in a memory (2) of a smart card (1), characterized in that it comprises steps of: deterministic preselection (100) in the memory (2), of at least one free zone having a size larger than the predetermined size, selection, (104) in a preselected free zone of a sub-zone having a size equal to the predetermined size, the selection of the sub-zone being variable for one same preselected free zone, use (106) of the selected sub-zone as allocated memory space.Type: ApplicationFiled: April 26, 2017Publication date: November 2, 2017Inventor: Pascal François Paul DUMAS
-
Publication number: 20110048593Abstract: The invention relates to a document case for receiving a large number of standardized format documents including at least two first flaps articulated relative to each other, the documents being inserted separately into overlapping pockets with an offset, their openings being parallel to the articulation axis of the flaps so that the documents are arranged in a stepped manner in order to expose a visible uncovered edge thereof. In case of two adjacent flaps, the steps are arranged with the same insertion direction, the highest document of one flap being adjacent to the lowest document of the other flap so that when the two flaps are folded on each other, the two series of steps are interleaved in order to reduce the thickness. Modes of application include wallets, multifunction diaries and document briefcases.Type: ApplicationFiled: October 17, 2007Publication date: March 3, 2011Inventor: Pascal Francois Jean Morand
-
Publication number: 20100280986Abstract: In various embodiments, systems and methods are provided for increasing the likelihood of a sustained virological response or “cure” using a model of patient physiology incorporating a subjects race, gender, age, weight, concomitant medicines and disease state, immune response status, and responsiveness to drug therapies to simultaneously characterize the change in viral burden in the subject in terms of velocity of viral load decline. In an embodiment, once viral load in a subject is below a physical measurement limit, the model can extrapolate the subject's observed viral velocity toward a physiological target shown to be highly correlated with “cure.” In further embodiments, the model can be used for personalized medicine—“the right drug at the right dose for the right treatment duration for the right patient.” Accordingly, the model can provide optimal value for treatment and reducing the high cost of side effects.Type: ApplicationFiled: May 4, 2009Publication date: November 4, 2010Applicant: Roche Palo AltoInventors: Eric Snoeck, Pascal Francois Chanu, Timothy Goggin, Nelson L. Jumbe, Nicolas Frey
-
Patent number: 5651007Abstract: A system of high availablity synchronous bandwidth allocation comprising an FDDI segment to which are connected a first device for allocating synchronous bandwidth over the FDDI segment to any requesting device, and at least a second device for requesting synchronous bandwidth over the FDDI segment. The first device and a third device also connected to said FDDI segment, are capable of a exchanging information regarding the allocation of synchronous bandwidth to at least the second device, the third device can take over for the first device as synchronous bandwidth allocator, if the first device fails.Type: GrantFiled: December 7, 1994Date of Patent: July 22, 1997Assignee: International Business Machines CorporationInventors: Jeffrey R. Warren, Eric Lebrun, Frederic Raimbault, Pascal Francois
-
Patent number: 5548579Abstract: To address Quality of Service (QoS) requirements in a domain of Local Area Networks(LANs) interconnected by at least one FDDI segment, network-wide bandwidth allocation is improved by a high availability Third Party Requestor (3PR) agent. The 3PR receives from the QoS Allocator all information that it needs to ask for bandwidth reservation on the FDDI segment. Following a Station Management standard, the 3PR is able to act on behalf of an FDDI station that will submit synchronous traffic and ask for bandwidth allocation to a Synchronous Bandwidth Allocator (SBA). According to the SBA decision, the 3PR will then answer to the network-centralized QoS Allocator which will grant or deny the allocation over the whole path within the LAN domain. If for some reason, the acting SBA function moves to another station, the 3PR at the new station will become active.Type: GrantFiled: June 21, 1995Date of Patent: August 20, 1996Assignee: International Business Machines CorporationInventors: Eric Lebrun, Pascal Francois, Frederic Raimbault, Jeff Warren
-
Patent number: 5479404Abstract: To solve the problem raised by the allocation of synchronous bandwidth on a FDDI segment when this allocation is done by a centralized Allocator in an interconnected LAN domain, a Third Party Requestor receives from Quality of Service Allocator all information that it needs to ask for bandwidth reservation on the FDDI segment. Following the Station Management standard, the Third Party Requestor is able to act on behalf of the FDDI station that will submit synchronous traffic and ask for bandwidth allocation to a Synchronous Bandwidth Allocator. According to the Synchronous Bandwidth Allocator decision, the Third Party Requestor will then answer to the Quality of Service Allocator which will grant or deny the allocation over the whole path.Type: GrantFiled: February 7, 1994Date of Patent: December 26, 1995Assignee: International Business Machines CorporationInventors: Pascal Francois, Eric Lebrun, Jeffrey R. Warren